encapsulated non-viral cell-based therapy secreting ARSB (Sigilon Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameencapsulated non-viral cell-based therapy secreting ARSB (Sigilon Therapeutics)

Drug Alias Nameencapsulated allogeneic human cells secreting arylsulfatase B (Sigilon Therapeutics)

ClassificationCell and gene therapy > Cell therapyBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionArylsulfatase B stimulants

TargetsArylsulfatase B

Therapy Area/IndicationsMucopolysaccharidosis VI

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSigilon Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSigilon Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsMucopolysaccharidosis VI

Other Information

ATC CodeN/A